Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
- Silverberg, JI, Guttman-Yassky, E, Thaçi, D, Irvine, AD, Stein Gold, L, Blauvelt, A et al.. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2023;388 (12):1080-1091. doi: 10.1056/NEJMoa2206714. PubMed PMID:36920778 .
- Team : Origins and pathogenesis of Autoimmune and Inflammatory disorders
- Axes : T2-Crosstalk between immune and epidermal cells